» Articles » PMID: 35138035

Joint Efficacy of the Three Biomarkers SNCA, GYPB and HBG1 for Atrial Fibrillation and Stroke: Analysis Via the Support Vector Machine Neural Network

Overview
Journal J Cell Mol Med
Date 2022 Feb 9
PMID 35138035
Authors
Affiliations
Soon will be listed here.
Abstract

Atrial fibrillation (AF) is the most common type of persistent arrhythmia. Although its incidence has been increasing, the pathogenesis of AF in stroke remains unclear. In this study, a total of 30 participants were recruited, including 10 controls, 10 patients with AF and 10 patients with AF and stroke (AF + STROKE). Differentially expressed genes (DEGs) were identified, and functional annotation of DEGs, comparative toxicogenomic database analysis associated with cardiovascular diseases, and predictions of miRNAs of hub genes were performed. Using RT-qPCR, biological process and support vector machine neural networks, numerous DEGs were found to be related to AF. HBG1, SNCA and GYPB were found to be upregulated in the AF group. Higher expression of hub genes in AF and AF + STROKE groups was detected via RT-PCR. Upon training the biological process neural network of SNCA and GYPB for HBG1, only small differences were detected. Based on the support vector machine, the predicted value of SNCA and GYPB for HBG1 was 0.9893. Expression of the hub genes of HBG1, SNCA and GYPB might therefore be significantly correlated to AF. These genes are involved in the incidence of AF complicated by stroke, and may serve as targets for early diagnosis and treatment.

Citing Articles

ANK1 inhibits malignant progression of osteosarcoma by promoting ferroptosis.

Zhang F, Wan J, Zhong J, Mo J BMC Cancer. 2024; 24(1):1075.

PMID: 39217322 PMC: 11365275. DOI: 10.1186/s12885-024-12836-z.


Expression profile of circulating miRNAs in patients with atrial fibrillation-dominated cardioembolic stroke: A systematic review and bioinformatics analysis.

Xiao X, Luo Z, Peng M, Yan H, Yi D, Du Z Heliyon. 2024; 10(15):e35201.

PMID: 39166047 PMC: 11334639. DOI: 10.1016/j.heliyon.2024.e35201.


Beneficial Effect of Edoxaban on Preventing Atrial Fibrillation and Coagulation by Reducing Inflammation HBG1/HBD Biomarkers.

Yang C, Wang X, Guo Y, Meng X, Li Y, Xia C Front Pharmacol. 2022; 13:904317.

PMID: 35721103 PMC: 9204214. DOI: 10.3389/fphar.2022.904317.


Joint efficacy of the three biomarkers SNCA, GYPB and HBG1 for atrial fibrillation and stroke: Analysis via the support vector machine neural network.

Wang X, Meng X, Meng L, Guo Y, Li Y, Yang C J Cell Mol Med. 2022; 26(7):2010-2022.

PMID: 35138035 PMC: 8980947. DOI: 10.1111/jcmm.17224.

References
1.
Rosian A, Rosian S, Kiss B, Stefan M, Trifa A, Ober C . Interindividual Variability of Apixaban Plasma Concentrations: Influence of Clinical and Genetic Factors in a Real-Life Cohort of Atrial Fibrillation Patients. Genes (Basel). 2020; 11(4). PMC: 7230214. DOI: 10.3390/genes11040438. View

2.
Ball J, Carrington M, McMurray J, Stewart S . Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century. Int J Cardiol. 2013; 167(5):1807-24. DOI: 10.1016/j.ijcard.2012.12.093. View

3.
Chen L, Bai J, Li Y . The Change of Interleukin-6 Level-Related Genes and Pathways Induced by Exercise in Sedentary Individuals. J Interferon Cytokine Res. 2020; 40(5):236-244. DOI: 10.1089/jir.2019.0169. View

4.
Gutierrez A, Van Wagoner D . Oxidant and Inflammatory Mechanisms and Targeted Therapy in Atrial Fibrillation: An Update. J Cardiovasc Pharmacol. 2015; 66(6):523-9. PMC: 4674316. DOI: 10.1097/FJC.0000000000000313. View

5.
Patrinos G, Kollia P, Papadakis M . Molecular diagnosis of inherited disorders: lessons from hemoglobinopathies. Hum Mutat. 2005; 26(5):399-412. DOI: 10.1002/humu.20225. View